vs
Side-by-side financial comparison of MAGNACHIP SEMICONDUCTOR Corp (MX) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
MAGNACHIP SEMICONDUCTOR Corp is the larger business by last-quarter revenue ($40.6M vs $23.0M, roughly 1.8× Intellia Therapeutics, Inc.). MAGNACHIP SEMICONDUCTOR Corp runs the higher net margin — -19.9% vs -416.2%, a 396.2% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -20.7%). MAGNACHIP SEMICONDUCTOR Corp produced more free cash flow last quarter ($-4.8M vs $-69.4M). Over the past eight quarters, MAGNACHIP SEMICONDUCTOR Corp's revenue compounded faster (-3.4% CAGR vs -10.8%).
Magnachip Semiconductor Corp is a global semiconductor design and manufacturing firm specializing in high-performance analog and mixed-signal solutions. Its core products include display driver ICs, power management ICs and sensors, serving consumer electronics, automotive, industrial and communications markets worldwide.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
MX vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $40.6M | $23.0M |
| Net Profit | $-8.1M | $-95.8M |
| Gross Margin | 9.3% | — |
| Operating Margin | -26.1% | -428.9% |
| Net Margin | -19.9% | -416.2% |
| Revenue YoY | -20.7% | 78.8% |
| Net Profit YoY | 50.4% | 25.7% |
| EPS (diluted) | $-0.23 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $40.6M | $23.0M | ||
| Q3 25 | $45.9M | $13.8M | ||
| Q2 25 | $47.6M | $14.2M | ||
| Q1 25 | $44.7M | $16.6M | ||
| Q4 24 | $51.2M | $12.9M | ||
| Q3 24 | $55.4M | $9.1M | ||
| Q2 24 | $46.4M | $7.0M | ||
| Q1 24 | $43.4M | $28.9M |
| Q4 25 | $-8.1M | $-95.8M | ||
| Q3 25 | $-13.1M | $-101.3M | ||
| Q2 25 | $323.0K | $-101.3M | ||
| Q1 25 | $-8.9M | $-114.3M | ||
| Q4 24 | $-16.3M | $-128.9M | ||
| Q3 24 | $-9.6M | $-135.7M | ||
| Q2 24 | $-13.0M | $-147.0M | ||
| Q1 24 | $-15.4M | $-107.4M |
| Q4 25 | 9.3% | — | ||
| Q3 25 | 18.6% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 20.9% | — | ||
| Q4 24 | 21.7% | — | ||
| Q3 24 | 20.8% | — | ||
| Q2 24 | 21.1% | — | ||
| Q1 24 | 14.6% | — |
| Q4 25 | -26.1% | -428.9% | ||
| Q3 25 | -25.1% | -808.9% | ||
| Q2 25 | -15.6% | -772.2% | ||
| Q1 25 | -14.1% | -726.6% | ||
| Q4 24 | -12.5% | -1059.9% | ||
| Q3 24 | -8.1% | -1589.0% | ||
| Q2 24 | -12.3% | -1998.6% | ||
| Q1 24 | -21.6% | -394.0% |
| Q4 25 | -19.9% | -416.2% | ||
| Q3 25 | -28.5% | -735.2% | ||
| Q2 25 | 0.7% | -710.8% | ||
| Q1 25 | -19.9% | -687.6% | ||
| Q4 24 | -31.8% | -1001.2% | ||
| Q3 24 | -17.3% | -1489.5% | ||
| Q2 24 | -28.0% | -2112.6% | ||
| Q1 24 | -35.5% | -371.3% |
| Q4 25 | $-0.23 | $-0.81 | ||
| Q3 25 | $-0.36 | $-0.92 | ||
| Q2 25 | $0.01 | $-0.98 | ||
| Q1 25 | $-0.24 | $-1.10 | ||
| Q4 24 | $-0.44 | $-1.27 | ||
| Q3 24 | $-0.26 | $-1.34 | ||
| Q2 24 | $-0.34 | $-1.52 | ||
| Q1 24 | $-0.40 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.8M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $248.3M | $671.4M |
| Total Assets | $351.5M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.8M | $449.9M | ||
| Q3 25 | $108.0M | $511.0M | ||
| Q2 25 | $113.3M | $459.7M | ||
| Q1 25 | $132.7M | $503.7M | ||
| Q4 24 | $138.6M | $601.5M | ||
| Q3 24 | $151.1M | $658.1M | ||
| Q2 24 | $162.5M | $691.1M | ||
| Q1 24 | $171.6M | $791.3M |
| Q4 25 | $248.3M | $671.4M | ||
| Q3 25 | $255.3M | $748.4M | ||
| Q2 25 | $270.2M | $715.3M | ||
| Q1 25 | $269.2M | $779.9M | ||
| Q4 24 | $276.8M | $872.0M | ||
| Q3 24 | $299.6M | $962.6M | ||
| Q2 24 | $305.8M | $971.1M | ||
| Q1 24 | $321.9M | $1.0B |
| Q4 25 | $351.5M | $842.1M | ||
| Q3 25 | $359.6M | $925.3M | ||
| Q2 25 | $370.5M | $898.9M | ||
| Q1 25 | $373.9M | $986.2M | ||
| Q4 24 | $379.3M | $1.2B | ||
| Q3 24 | $411.4M | $1.2B | ||
| Q2 24 | $412.7M | $1.2B | ||
| Q1 24 | $426.2M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.4M | $-69.3M |
| Free Cash FlowOCF − Capex | $-4.8M | $-69.4M |
| FCF MarginFCF / Revenue | -11.9% | -301.6% |
| Capex IntensityCapex / Revenue | 25.3% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-54.2M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.4M | $-69.3M | ||
| Q3 25 | $162.0K | $-76.9M | ||
| Q2 25 | $-25.1M | $-99.6M | ||
| Q1 25 | $-4.7M | $-148.9M | ||
| Q4 24 | $11.9M | $-85.2M | ||
| Q3 24 | $-12.9M | $-84.8M | ||
| Q2 24 | $-1.1M | $-58.2M | ||
| Q1 24 | $-4.0M | $-120.7M |
| Q4 25 | $-4.8M | $-69.4M | ||
| Q3 25 | $-7.5M | $-76.9M | ||
| Q2 25 | $-37.0M | $-99.9M | ||
| Q1 25 | $-4.9M | $-149.7M | ||
| Q4 24 | $4.4M | $-86.2M | ||
| Q3 24 | $-15.5M | $-86.1M | ||
| Q2 24 | $-2.0M | $-59.2M | ||
| Q1 24 | $-4.6M | $-123.2M |
| Q4 25 | -11.9% | -301.6% | ||
| Q3 25 | -16.3% | -558.2% | ||
| Q2 25 | -77.7% | -701.0% | ||
| Q1 25 | -10.9% | -900.1% | ||
| Q4 24 | 8.7% | -669.4% | ||
| Q3 24 | -28.0% | -945.2% | ||
| Q2 24 | -4.3% | -850.9% | ||
| Q1 24 | -10.7% | -425.7% |
| Q4 25 | 25.3% | 0.5% | ||
| Q3 25 | 16.7% | 0.2% | ||
| Q2 25 | 24.9% | 1.7% | ||
| Q1 25 | 0.5% | 4.4% | ||
| Q4 24 | 14.5% | 7.6% | ||
| Q3 24 | 4.7% | 14.0% | ||
| Q2 24 | 1.9% | 14.5% | ||
| Q1 24 | 1.5% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -77.81× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MX
| Power Analog Solutions | $36.8M | 91% |
| Power Ic | $3.8M | 9% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
